Antibiotic resistance startup gets $33M from Boehringer, Novo; Equillium bags a tri-specfic
Centauri Therapeutics has closed a £24 Million Series A investment round to support the advancement of its antimicrobial resistance R&D work, using its Alphamer platform.
Boehringer Ingelheim Venture Fund, Evotec SE, and Novo Holdings REPAIR Impact Fund all led the round while existing investors Animatrix Founders LLP, Kent Life Science and Wren Capital also contributed.
Boehringer’s Johannes Zanzinger, Evotec’s Karen Lackey, and Novo Holdings’ Camilla Petrycer Hansen will all join the board of directors. In a statement, Hansen said:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.